Imagine your thumb joint is like a rusty hinge that makes every grip painful. Instead of just removing the bone or using a generic fix, this project created a custom-fit replacement part that moves exactly like a natural thumb. It's designed to stop the pain and bring back the strength you need to open jars or hold a pen.
Thumb base joint arthritis causes pain and restricts hand use for millions, with current surgical options often failing to restore natural biomechanics and full joint power.
A patented biomechanical thumb implant (InDx) and a supporting Health Economics dossier based on clinical trial data.
If you are an orthopedic implant manufacturer dealing with a lack of biomechanically accurate thumb solutions — this project developed the InDx Implant that mimics natural hand motion. This allows for a more reliable clinical outcome compared to existing surgical options.
If you are a surgical clinic dealing with an aging population where 5% of EU citizens seek medical intervention for thumb arthritis — this project developed a simpler-to-insert implant. This increases patient throughput and improves quality of life scores.
If you are a reimbursement agency dealing with high long-term costs of failed joint surgeries — this project developed a Health Economics dossier and evidence-based implant. This ensures better long-term patient outcomes and clearer cost-benefit analysis.
The potential market for the treatment of thumb base joint arthritis is estimated at over €700M per year.
The InDx Implant is patented, and the company has further added to its existing intellectual property portfolio during the project.
The company is using clinical investigation data to advance regulatory clearance in both the EU and the US.
Based on available project data, the specific unit price or cost of the implant is not disclosed.
Based on available project data, the project focused on clinical trials and reimbursement strategy; specific industrial manufacturing scale details are not provided.
The project concluded in April 2024, with commercialization planning for the EU and US initiated following regulatory clearance.
The project is led by a single SME, Loci Orthopaedics Limited from Ireland. This 100% industry-led structure indicates a highly focused commercial drive, with the coordinator acting as both the innovator and the entity responsible for regulatory and reimbursement strategies.
Contact Loci Orthopaedics Limited in Ireland for licensing or partnership inquiries.
Contact SciTransfer for a detailed analysis of the InDx Implant's clinical trial results.
